DFP-10917

DFP-10917 is a nucleoside analogue (continuous intravenous infusion) from Delta-Fly Pharma, with Nippon Shinyaku as licensee. A deoxycytidine-like nucleoside analogue given as a low-dose continuous infusion over 14 days. Its furthest stage is phase 3, for relapsed or refractory acute myeloid leukaemia. ClinicalTrials.gov registers it in 3 studies linked below. The phase 3 trial NCT03926624 in relapsed or refractory AML was TERMINATED: 'The data met the protocol-specified criteria for futility of the investigational treatment' (167 enrolled; completed 7 January 2026). A phase 1/2 with venetoclax (NCT06382168) has registry status UNKNOWN. No company statement on next steps was found. Whether it works in people has not been established unless a trial below reports it.